Encoded Therapeutics Reports Durable Seizure Reduction and Neurodevelopmental Gains With ETX101 in Dravet Syndrome Encoded Therapeutics, Inc., a clinical-stage biotechnology company focused on developing precision genetic medicines for severe neurological disorders, has announced new Phase 1/2 clinical data for ETX101,…
GenSight Biologics Provides Summer 2026 Business and Clinical Development Updates GenSight Biologics, a biopharmaceutical company specializing in the development and commercialization of innovative gene therapies for retinal neurodegenerative diseases and disorders of the central nervous system (CNS), has announced a…
Segal Trials Employees Join CISCRP Medical Heroes Appreci-A-Thon to Honor Clinical Research Participants and Professionals More than 90 employees from Segal Trials are participating in the 8th Annual Medical Heroes Appreci-A-Thon organized by the Center for Information and Study on…
Gabrail Cancer and Research Center Receives FDA Clearance to Advance STAR-LLD and Elranatamab Study in Multiple Myeloma The Gabrail Cancer and Research Center, a PhaseWell Research site, has announced an important regulatory milestone for an investigator-initiated clinical trial evaluating STAR-LLD…
Cencora Launches Cell and Gene Therapy Enablement Service to Help Health Systems Expand Advanced Therapy Programs Cencora has launched a new service designed to help health systems evaluate, establish, and scale cell and gene therapy (CGT) programs as the number…
Naturmega to Introduce SUPRIAX2™ and Showcase Next-Generation Lipid Innovation at SupplySide Global 2026 Naturmega, an advanced lipid science company focused on omega-3 and next-generation lipid technologies, is preparing to introduce SUPRIAX2™ to the North American market at SupplySide Global 2026…
Agenus Reports Updated NEST Phase 2 Results Supporting Neoadjuvant BOT+BAL in Colon Cancer Agenus Inc. (Nasdaq: AGEN), a biotechnology company focused on immuno-oncology innovation, has announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST clinical trial…
Axoft Introduces Fleuron WISE Elastomer to Enable High-Resolution Imaging in Aqueous Environments Axoft, a neurotechnology company developing advanced materials and technologies for applications at the intersection of biology and electronics, has announced the introduction of Fleuron® Water Invisible Soft Elastomer…
GeneDx Study Shows Hospital-Wide Rapid Genome Sequencing Can Improve Pediatric Diagnosis, Outcomes and Health System Efficiency GeneDx (Nasdaq: WGS), a company focused on rare disease diagnosis and the use of genomic information to improve health outcomes, has announced new findings…
European Commission Broadens Trodelvy’s First-Line Use in Metastatic Triple-Negative Breast Cancer Regardless of PD-L1 Status Gilead Sciences, Inc.announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the first-line treatment…
Genentech to Invest $750 Million in New Device Fill-Finish Manufacturing Facility in Oregon Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), has announced plans to invest approximately $750 million to establish a new device fill-finish manufacturing…
Regenerative Research Foundation Selected as a Winner of NIH’s Complement-ARIE Challenge The Regenerative Research Foundation has announced that its Neural Stem Cell Institute (NSCI) has been selected as a Phase 1 winner in the National Institutes of Health’s (NIH) Complement-ARIE…